About TD2
TD2 is a company based in Phoenix (United States) founded in 2003 was acquired by RCT in June 2020. The company has 119 employees as of December 31, 2021. TD2 offers products and services including Clinical Trial Services, Preclinical Services, Regulatory Support, and Flow Cytometry Services. TD2 operates in a competitive market with competitors including GSK, Avidity Biosciences, Vividion Therapeutics, Korro Bio and Sutro Biopharma, among others.
- Headquarter Phoenix, United States
- Employees 119 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Translational Drug Development, Llc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
119
as on Dec 31, 2021
-
Acquired by
RCT
(Jun 04, 2020)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TD2
TD2 offers a comprehensive portfolio of products and services, including Clinical Trial Services, Preclinical Services, Regulatory Support, and Flow Cytometry Services.
Design and execution of oncology clinical trials
Development of cancer models and bioanalytical services
Assistance with IND filings and FDA interactions
Analysis of drug effects on immune cells
People of TD2
Unlock access to complete
Funding Insights of TD2
Detailed funding history for TD2
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in TD2
TD2 has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Research Corporation Technologies.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research Corporation Technologies is engaged in licensing biomedical technologies.
|
Locked | Locked | Locked |
Investor details for TD2
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TD2
Investment portfolio details for TD2
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TD2
Detailed financials for TD2
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Td2 Comparisons
Peer comparison for TD2
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TD2
TD2 operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Vividion Therapeutics, Korro Bio and Sutro Biopharma, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Therapeutics for rare respiratory diseases are developed by Savara Pharma.
|
Detailed competitors of TD2
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Td2
Complete news archive for TD2
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TD2
TD2 was founded in 2003.
TD2 is headquartered in Phoenix, United States. It is registered at Phoenix, Arizona, United States.
As of Dec 31, 2021, the latest employee count at TD2 is 119.
Translational Drug Development (TD2), a wholly owned subsidiary of the Translational Genomics Research Institute (TGen) is an oncology drug development organization that provides services for oncology-focused biopharmaceutical companies. It provides pre-clinical services like in vitro myeloma screening tools, in vivo imaging capabilities, image-guided micro-irradiation labs, and specialized tumor models. Besides, it offers bioanalysis and DMPK facilities. Additionally, it also offers regulatory and clinical services like FDA regulations, pre-Investigational New Drug (IND) application and IND strategies, IND submissions, FDA-regulated trials, Good Laboratory Practices (GLP); ToxicologyPharmacology Support Services.
TD2's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
TD2 offers Clinical Trial Services, Preclinical Services, Regulatory Support, and Flow Cytometry Services.
TD2 has 1 investor. Key investors include Research Corporation Technologies.